Articles tagged with Prostate Cancer
A study found that both web-based and print-based decision aids significantly improved prostate cancer knowledge and reduced decisional conflict among patients. The tools offered flexibility for patients and providers, with increased satisfaction reported among those using print decision aids up to 13 months after treatment.
A Swedish data-sharing campaign led to a significant decrease in unnecessary medical tests for low-risk prostate cancer patients. The study suggests that curtailing unneeded medical tests is achievable and offers insights into the importance of implementing guidelines and providing feedback to practitioners.
A study of over 10,000 men with nonmetastatic prostate cancer found that use of androgen deprivation therapy (ADT) was associated with a significantly increased risk of acute kidney injury. The association remained consistently elevated across different types of ADTs, particularly in the first year of treatment.
Researchers at Albert Einstein College of Medicine have found that nerves play a critical role in both the development and spread of prostate tumors. The study suggests that targeting the autonomic nervous system may lead to novel therapies for preventing and treating prostate cancer.
A large prospective study by Fred Hutchinson Cancer Center scientists confirms the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer. High-grade prostate cancer tumors are more likely to be fatal, and the study found a 71% higher risk for high-grade prostate cancer.
A study published in JAMA found that daily soy protein supplementation for two years did not reduce or delay the development of biochemical recurrence of prostate cancer. In fact, the supplement may even accelerate the onset of recurrence by a few weeks.
Researchers found that most men report little shared decision making in PSA screening, with only 8% reporting full shared decision making. Coupling physician education with patient activation improves rates of shared decision making and influences physicians' attitudes about screening.
Use of advanced treatment technologies like IMRT and robotic prostatectomy has increased among men with low-risk disease, despite clinical guidelines recommending local treatment for those with a low life expectancy. The authors suggest that aggressive direct-to-consumer marketing and incentives may promote the use of these treatments.
A Johns Hopkins study of over 1,800 men aged 52-62 suggests that African-Americans with very-low-risk prostate cancers are more likely to have aggressive disease. The study found a higher rate of Gleason score upgrading and organ-confined cancers among black men, highlighting the need for race-specific surveillance entry criteria.
Researchers have identified genetic variants that can predict aggressive prostate cancers, enabling better treatment options for patients. The study's findings suggest a novel relationship between angiogenesis genes and prostate cancer aggressiveness.
A study by Dana-Farber Cancer Institute researchers found that active surveillance and watchful waiting are safe alternatives to initial treatment for men with low-risk prostate cancers. These strategies can lead to better quality of life and reduced healthcare costs, with some patients experiencing up to 13 months additional quality-a...
A new study by The Endocrine Society finds that early exposure to BPA significantly increases the risk of both prostate cancer and a precancerous condition known as prostate epithelial neoplasia. The study used human prostate stem cells from organ donors to grow prostate tissue in a mouse model.
A new study by University of Illinois Chicago researcher Gail Prins found that early exposure to BPA in the developing prostate increases the risk of later prostate cancer. Prostate stem cells become sensitized to estrogen through BPA exposure, making them more susceptible to cancer development.
A new drug called pyrvinium pamoate inhibits aggressive prostate cancer resistant to standard drugs by binding to a different site on the AR and inhibiting its activity without preventing androgen binding. This unique mechanism of action has the potential to treat cancers resistant to currently approved therapies.
Researchers discovered a molecular switch, Steroidogenic Factor 1, that stimulates steroid hormone production and cell multiplication in aggressive prostate cancers. This factor increases tumor growth and resistance to hormone treatment.
Researchers have developed a novel imaging agent, Tc-99m MIP-1404, which binds to PSMA enzyme in prostate cancer cells, enabling detection of metastases. The agent shows promise in detecting lesions more accurately than standard bone imaging.
Replacing carbohydrates with vegetable fat may be associated with a lower risk of death in men with nonmetastatic prostate cancer, according to a study published in JAMA Internal Medicine. The study found that men who consumed more vegetable fat had a lower risk of lethal prostate cancer and all-cause mortality.
A new biodegradable implant has shown potential to significantly reduce rectal injury in prostate cancer patients undergoing radiation therapy. The BioProtect Balloon Implant increased the space between the prostate and rectum, reducing radiation exposure by an average of 30%.
A UC San Francisco-led study found that men with non-metastatic prostate cancer who consumed more healthy vegetable fats had a lower risk of developing lethal prostate cancer and dying from other causes. Replacing 10% of daily calories with these fats was associated with a 29% lower risk of lethal prostate cancer.
A new hybrid molecular imaging system combines positron emission tomography and magnetic resonance to detect recurrent prostate cancer. The study reveals that PET/MR finds more areas of metastases than PET/CT, making it a viable alternative for restaging patients with metastatic prostate cancer.
Scientists use antigen-decorated nanoparticles to prevent immune over-reaction in mice, while also developing a potential gene therapy for Mucopolysaccharidosis Type IIIA. Meanwhile, researchers discover a new target for castration-resistant prostate cancer by blocking mutant androgen receptors.
Researchers at Monash University have identified a sub-group of cells that can contribute to prostate cancer recurrence, opening up new treatment options. These previously unidentified cells are potential targets for future therapies and may be targeted before the cancer reaches an incurable stage.
A recent study published in Cancer found that African American men with prostate cancer face longer treatment delays than their Caucasian counterparts. The analysis of SEER-Medicare registry data revealed an average delay of 7 days for African American patients, compared to 4 days for Caucasians. Additionally, African Americans were mo...
Researchers developed a novel class of peptidomimetic drugs that interrupt androgen receptor signaling in prostate cancer cells, preventing growth. The agents show promise as a potential therapeutic approach for men with advanced disease.
Researchers have developed a device that captures and isolates potentially high-risk cancer cells, enabling doctors to access and identify cancerous cells in the bloodstream. This technology may revolutionize conventional biopsy practices and significantly advance personalized medicine.
A novel small molecule has been developed to block the function of androgen receptors, which promote prostate cancer growth. The compound prevents cancer cells from recruiting protein partners and blocks their growth, showing promise for treating prostate cancer.
Researchers used next-generation sequencing to analyze DNA alterations in adjacent Gleason patterns of the same tumor. The study found that some aggressive prostate cancers have identical genetic markers, enabling better prediction of cancer progression and management.
Researchers have created a low-cost and accurate method for detecting prostate cancer in urine, potentially leading to early diagnosis and improved treatment outcomes. The technology uses nanoscale protein receptors to capture cancer molecule signals, offering a promising alternative to existing tests that can be costly and invasive.
A 14-year study found older men with multiple health issues were at higher risk of dying from other causes, making watchful waiting a viable option for low- to intermediate-risk prostate cancer patients.
A recent study published in JAMA Internal Medicine found that intensity-modulated radiation therapy (IMRT) may not be more effective than conformal radiation therapy (CRT) after prostatectomy. The study compared outcomes of 457 IMRT and 557 CRT patients treated between 2002 and 2007, showing no significant difference in long-term side ...
Studies of newly diagnosed prostate cancer patients reveal that older, sicker men are unlikely to benefit from aggressive therapy. Researchers found that those aged 61-74 and over 75 with multiple health issues face high risks of mortality from non-prostate causes, suggesting a shift towards more conservative treatment approaches.
A new UCI study found that assessing comorbidities can help target prostate cancer patients who may not benefit from a biopsy, potentially reducing unnecessary procedures. The study identified 20% of men as high-risk due to existing health conditions, suggesting alternative care options.
A new study found that bone mineral density testing is not routine among men receiving androgen deprivation therapy, but those with primary care physicians are more likely to receive the test. This highlights the importance of primary care physicians in bone care for men with prostate cancer.
A new analysis found a significant link between Agent Orange exposure and high-grade prostate cancer among US Veterans. Exposure to the herbicide was associated with a 52% increase in overall risk of prostate cancer detection by biopsy, as well as a 75% increase in risk of high-grade prostate cancer.
A new genomic test helps identify low-risk men suitable for active surveillance, sparing them from unnecessary treatment. The test provides statistically significant and clinically meaningful prognostic information, aiding in determining which men are best suited for active surveillance.
Researchers found that combining tomato and soy foods reduced prostate cancer incidence by 55% compared to eating either food alone. The study suggested that consuming three to four servings of tomato products per week and one to two servings of soy foods daily could help protect against prostate cancer.
A study by Thomas Jefferson University researchers found that amplification of the Stat5 gene in prostate cancer cells leads to excess oncogenic protein, driving cancer spread. Gene amplification and protein levels increased with metastasis and castration therapy resistance.
The new guideline provides detailed direction on treatment options for prostate cancer patients, including adjuvant and salvage radiotherapy recommendations. It emphasizes the importance of informed consent and patient education on potential side effects and benefits of radiation therapy.
A recent study by Henry Ford Health reveals that prostate cancer patients with metastasis are more likely to die after weekend emergency department visits compared to weekdays. The study found that these patients have a 23% increased likelihood of death after weekend visits, despite being older and healthier on average.
A new study reveals that surgical volume significantly affects the outcome of procedures, especially for robotic-assisted surgeries. High-volume hospitals demonstrated superior results in terms of complication rates and blood transfusions, while low-volume centers struggled with inferior outcomes.
Researchers found that men with prostate cancer who take statin drugs are significantly less likely to die from their cancer. The study, led by Janet L. Stanford, Ph.D., followed over 1,000 Seattle-area prostate cancer patients for almost eight years and found a 5% mortality rate among statin users versus 1% for nonusers.
A new study reveals that prostate cancer develops through periodic bursts of genetic mutations, causing complex DNA reshuffling. This process, dubbed 'punctuated cancer evolution,' may lead to more accurate diagnosis and effective treatment in the future.
A new study from Northwestern University suggests that personalized PSA testing can help reduce the number of men who undergo unnecessary biopsies. Genetic correction of PSA levels using genetic variants has been shown to change the outcome for 17 men, and could potentially prevent 15-20% of prostate biopsies annually.
Researchers found obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared to non-obese men. Obesity was also associated with a significantly higher risk of developing prostate cancer after an initial benign biopsy, particularly in the first few years after.
Research found that specific DNA regions contribute to prostate cancer development and early death, with patients having two of these changes at high risk. The study identifies key genes PTEN and MYC as linked to prostate cancer lethality.
Multispectral photoacoustic imaging distinguishes between benign and malignant prostate tissue with a high degree of accuracy. The new technique, which combines laser optics and ultrasound imaging technologies, predicts 25 out of 26 benign tissues and 13 out of 16 malignant tissues correctly.
A new study suggests that nearly half of all deaths from prostate cancer can be predicted before age 50, based on PSA levels. Focusing testing on men at highest risk may improve the benefits and harms of screening.
Researchers at Massachusetts General Hospital identified a genetic signature associated with the risk of tumor recurrence or spread in men surgically treated for prostate cancer. The 32-gene index proved to be the most accurate method, predicting actual incidence of tumor recurrence (47%) and metastasis (14%) among high-risk patients.
A new study reveals that correcting PSA levels for genetic variants can significantly reduce unnecessary biopsies and false complacency. By tailoring screening levels to an individual's genetic makeup, the risk of prostate cancer can be more accurately assessed. This approach has the potential to prevent up to 15% to 20% of biopsies.
Researchers identified BRCA2 gene mutation as first genetic factor for prostate cancer prognosis, associated with advanced disease and higher mortality rates. The study suggests a need for new treatment strategies for patients carrying these mutations.
The American College of Physicians suggests that men between 50-69 discuss potential benefits and harms of the PSA test before screening. The risks include problems interpreting test results, biopsy complications, and treatment side effects. ACP recommends against testing in men younger than 50 or older than 69 with low life expectancy.
The American College of Physicians (ACP) releases new recommendations for prostate cancer screening, focusing on shared decision-making and clear patient preference. Men between 50-69 years old should discuss the benefits and harms of PSA testing with their doctor before undergoing screening. The ACP also recommends against screening f...
Researchers at Virginia Tech have identified a genetically engineered Newcastle disease virus as a potential treatment for prostate cancer. The virus efficiently kills prostate cancer cells, including those resistant to hormone treatments and chemotherapy, while sparing normal human cells.
Researchers have developed a non-invasive test for metastatic prostate cancer using whole-genome analysis of plasma DNA, which identifies abnormal copy numbers of specific sequences. This breakthrough could aid personalized therapy and target treatment for castration-resistant prostate cancer.
A new study of 1,535 patients with metastatic hormone-sensitive prostate cancer found that taking breaks from hormone-blocking treatments may not be as effective as continuous treatment. The study suggests that patients should be counseled about the potential risks of intermittent therapy if they wish to try it.
A study published in the New England Journal of Medicine recommends continuous hormone therapy for metastatic prostate cancer, extending lives by months to years. Continuous therapy offers a better alternative to intermittent therapy with fewer side effects.
A CU Cancer Center study reveals that the transcription factor SPDEF regulates E-Cadherin production, inhibiting prostate cancer metastasis. The researchers found that increasing or decreasing SPDEF levels directly affects E-Cadherin expression, making it a crucial factor in preventing cancer spread.
Researchers at Sanford-Burnham Medical Research Institute discovered that the enzyme PKCζ acts as a tumor suppressor in both mice and humans, controlling cell growth and metastasis. Restoring PKCζ levels may provide a novel therapeutic target for treating prostate cancer.
Researchers found that SPOP mutations allow SRC-3 to proliferate and spread prostate cancer cells. The loss of SPOP's tumor-suppressing function enables SRC-3's cancer-promoting effects, making it an important target for prostate cancer treatment.
A new study links Lynch syndrome to a higher lifetime risk of prostate cancer and earlier age of onset, suggesting regular screening for men with the condition. The research estimates that men with Lynch syndrome have a 30% lifetime risk of developing prostate cancer, compared to 18% in the general population.